American Society of Hirudotherapy

Pulmonary embolus

Research article published in Australian journal of general practice (2022)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsDix et al. · Australian journal of general practice, 2022

Abstract

BACKGROUND: Pulmonary embolism (PE) remains a common problem and can present with nonspecific symptoms and signs. Anticoagulation is the mainstay of management, the duration of which often depends on the clinical circumstances of the PE. OBJECTIVE: The aim of this article is to review the epidemiology, clinical presentation, diagnosis, management and long-term complications of PE. DISCUSSION: The incidence of PE appears to be increasing worldwide. Common risk factors include recent surgery, trauma, malignancy and oestrogen exposure. Diagnosis relies on a combination of clinical findings, laboratory tests and radiological imaging, often incorporating clinical prediction tools. Objectively confirmed PE requires anticoagulation, usually with a direct oral anticoagulant (DOAC), of at least three months' duration, but indefinite anticoagulation is being considered increasingly because of the heightened risk for recurrence following anticoagulation cessation, and overall safety of DOACs. Chronic thromboembolic pulmonary hypertension is rare but associated with significant morbidity and mortality.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnticoagulantsHumansIncidencePulmonary EmbolismRisk Factors

Summary

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This review (Dix et al., 2022) summarizes the epidemiology, presentation, diagnosis, management, and long-term complications of pulmonary embolism, noting that anticoagulation, usually with a direct oral anticoagulant for at least three months, is the mainstay of treatment and that indefinite anticoagulation is increasingly considered given recurrence risk. It is useful ASH context because it situates leech therapy and the leech secretome's natural anticoagulants within the dominant clinical picture of venous thromboembolism, where systemic, dosed anticoagulation, not topical leeching, is the established standard of care. Caveat: this is a narrative review of established practice and makes no claim about hirudotherapy; medicinal leeches have no role in treating pulmonary embolism, and the article is cited here only for the surrounding anticoagulation evidence base.

Citation

Pulmonary embolus.

Dix et al. · Australian journal of general practice, 2022

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.